文献速递骨软组织肉瘤与黑色素瘤

SREBP2诱导循环黑色素瘤细胞转铁蛋白并抑制铁死亡

The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis.
PubMed 文献 · Cancer Discov · 2020-11-17

该研究通过对黑色素瘤患者循环肿瘤细胞(CTC)的单细胞分析,发现CTC协调上调脂质合成与铁稳态通路,SREBP2直接诱导转铁蛋白(TF)转录,降低细胞内铁池、活性氧和脂质过氧化,从而抵抗铁死亡诱导剂。敲低TF可损害CTC成瘤能力,且该缺陷可被铁死亡抑制剂部分挽救。前瞻性队列中,高脂质合成和铁代谢RNA特征的CTC与不良临床结局相关,不受治疗方案影响。

要点

  • 黑色素瘤CTC上调脂质合成与铁稳态通路,SREBP2直接诱导TF转录。
  • SREBP2/TF轴降低细胞内铁和脂质过氧化,赋予CTC对铁死亡诱导剂的抗性。
  • 高脂质合成和铁代谢RNA特征的CTC与不良临床结局相关。

核心结论

  • SREBP2驱动的铁稳态通路促进黑色素瘤进展、耐药和转移。
  • CTC中脂质合成和铁代谢通路的激活与不良临床结局相关,提示治疗机会。

研究设计与样本

  • 对黑色素瘤患者原代和培养的CTC进行单细胞分析。
  • 在前瞻性黑色素瘤队列中评估CTC的脂质合成和铁代谢RNA特征与临床结局的关系。

主要发现

  • 来自黑色素瘤患者的单个CTC协调上调脂质合成和铁稳态通路。
  • 这些通路与BRAF突变CTC克隆培养中对BRAF抑制剂的固有和获得性耐药相关。
  • SREBP2直接诱导转铁蛋白(TF)转录,降低细胞内铁池、活性氧和脂质过氧化,从而赋予对铁死亡诱导剂的抗性。
  • 敲低内源性TF损害黑色素瘤CTC的成瘤能力,其成瘤缺陷可被亲脂性抗氧化剂ferrostatin-1和维生素E部分挽救。
  • 在前瞻性黑色素瘤队列中,具有高脂质合成和铁代谢RNA特征的CTC与不良临床结局相关, irrespective of treatment regimen。

临床怎么用

  • CTC的脂质合成和铁代谢RNA特征可能作为预后标志物。
  • 靶向SREBP2/TF轴或铁死亡通路可能克服BRAF抑制剂耐药和抑制转移。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Circulating tumor cells (CTC) are shed by cancer into the bloodstream, where a viable subset overcomes oxidative stress to initiate metastasis. We show that single CTCs from patients with melanoma coordinately upregulate lipogenesis and iron homeostasis pathways. These are correlated with both intrinsic and acquired resistance to BRAF inhibitors across clonal cultures of BRAF-mutant CTCs. The lipogenesis regulator SREBP2 directly induces transcription of the iron carrier Transferrin (TF), reducing intracellular iron pools, reactive oxygen species, and lipid peroxidation, thereby conferring resistance to inducers of ferroptosis. Knockdown of endogenous TF impairs tumor formation by melanoma CTCs, and their tumorigenic defects are partially rescued by the lipophilic antioxidants ferrostatin-1 and vitamin E. In a prospective melanoma cohort, presence of CTCs with high lipogenic and iron metabolic RNA signatures is correlated with adverse clinical outcome, irrespective of treatment regimen. Thus, SREBP2-driven iron homeostatic pathways contribute to cancer progression, drug resistance, and metastasis. SIGNIFICANCE: Through single-cell analysis of primary and cultured melanoma CTCs, we have uncovered intrinsic cancer cell heterogeneity within lipogenic and iron homeostatic pathways that modulates resistance to BRAF inhibitors and to ferroptosis inducers. Activation of these pathways within CTCs is correlated with adverse clinical outcome, pointing to therapeutic opportunities.This article is highlighted in the In This Issue feature, p. 521.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Hong X, Roh W, Sullivan RJ, et al. The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis. Cancer Discov. 2020. PMID: 33203734. doi:10.1158/2159-8290.CD-19-1500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。